At that time, standard treatment involved the complete surgical removal of the tumors, followed by a long-term regimen of high-dose Mitotane, a medication that has been on the market since 1960. Mitotane, while effective for a certain group of patients, is known for its severe side effects. Thanks to a combination of high quality medical care, the loving and caring support of my family, but most of all a lot of luck, I was able to survive. Despite significant advances in cancer research and technology, today the standard therapy for ACC has remained largely unchanged since my initial diagnosis. Unfortunately, because of the rarity of ACC, funding for research is limited, and progress in treatment options has therefor been slow. Understanding the need for progress in ACC research, we have committed ourselves to long-term support of outstanding ACC research. Those efforts are intended to lead to improved treatments and outcomes for ACC patients in the future.

Most recently he was a management team member at Teslin. In addition to his professional career, Roderik has always been very socially engaged a.o. as treasurer at the Dioraphte Foundation and Haella Foundation. Roderik is the treasurer of the NAC Foundation.

Funding for ACC research that improves patient outcome clearly deserves our full attention. In my own professional experience in the field of hemato-oncology I have seen how innovative research initiatives can lead the way to clinical advances and progressive improvements in patient survival and quality of life. It is a privilege for me to team up with the NAC Foundation because of its determined commitment to fund high-level scientific research with the focus on creating better perspectives for patients with ACC.

It is therefore fantastic that there is now a foundation that will support research in this area, and it was an honor and a matter of course for me to immediately accept a position on the foundation’s board.